NASDAQ:RCEL

AVITA Medical Competitors

$20.62
-0.14 (-0.67 %)
(As of 04/14/2021 03:19 PM ET)
Add
Compare
Today's Range
$20.62
Now: $20.62
$20.99
50-Day Range
$19.24
MA: $21.47
$25.10
52-Week Range
$16.87
Now: $20.62
$34.95
Volume3,029 shs
Average Volume163,688 shs
Market Capitalization$445.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05

Competitors

AVITA Medical (NASDAQ:RCEL) Vs. GNMK, LMNX, SILK, ATEC, LUNG, and CSII

Should you be buying RCEL stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to AVITA Medical, including GenMark Diagnostics (GNMK), Luminex (LMNX), Silk Road Medical (SILK), Alphatec (ATEC), Pulmonx (LUNG), and Cardiovascular Systems (CSII).

AVITA Medical (NASDAQ:RCEL) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Valuation & Earnings

This table compares AVITA Medical and GenMark Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVITA Medical$14.26 million31.28$-42,030,000.00($2.07)-9.96
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26

AVITA Medical has higher earnings, but lower revenue than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for AVITA Medical and GenMark Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVITA Medical00403.00
GenMark Diagnostics05002.00

AVITA Medical presently has a consensus target price of $38.75, suggesting a potential upside of 86.75%. GenMark Diagnostics has a consensus target price of $22.0125, suggesting a potential downside of 8.24%. Given AVITA Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe AVITA Medical is more favorable than GenMark Diagnostics.

Profitability

This table compares AVITA Medical and GenMark Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVITA MedicalN/AN/AN/A
GenMark Diagnostics-16.95%-39.36%-13.02%

Insider and Institutional Ownership

15.9% of AVITA Medical shares are held by institutional investors. Comparatively, 96.9% of GenMark Diagnostics shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

AVITA Medical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, indicating that its share price is 202% more volatile than the S&P 500.

Summary

AVITA Medical beats GenMark Diagnostics on 9 of the 14 factors compared between the two stocks.

AVITA Medical (NASDAQ:RCEL) and Luminex (NASDAQ:LMNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Valuation & Earnings

This table compares AVITA Medical and Luminex's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVITA Medical$14.26 million31.28$-42,030,000.00($2.07)-9.96
Luminex$334.64 million5.21$-3,840,000.00($0.21)-175.48

Luminex has higher revenue and earnings than AVITA Medical. Luminex is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AVITA Medical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares AVITA Medical and Luminex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVITA MedicalN/AN/AN/A
Luminex4.60%3.75%2.73%

Analyst Recommendations

This is a breakdown of recent recommendations for AVITA Medical and Luminex, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVITA Medical00403.00
Luminex03002.00

AVITA Medical presently has a consensus target price of $38.75, suggesting a potential upside of 86.75%. Luminex has a consensus target price of $37.00, suggesting a potential upside of 0.76%. Given AVITA Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe AVITA Medical is more favorable than Luminex.

Insider and Institutional Ownership

15.9% of AVITA Medical shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 9.4% of Luminex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Luminex beats AVITA Medical on 9 of the 14 factors compared between the two stocks.

AVITA Medical (NASDAQ:RCEL) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares AVITA Medical and Silk Road Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVITA Medical$14.26 million31.28$-42,030,000.00($2.07)-9.96
Silk Road Medical$63.35 million27.94$-52,420,000.00($1.36)-37.87

AVITA Medical has higher earnings, but lower revenue than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

AVITA Medical has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Profitability

This table compares AVITA Medical and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVITA MedicalN/AN/AN/A
Silk Road Medical-53.66%-40.79%-24.56%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AVITA Medical and Silk Road Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVITA Medical00403.00
Silk Road Medical02202.50

AVITA Medical currently has a consensus target price of $38.75, suggesting a potential upside of 86.75%. Silk Road Medical has a consensus target price of $61.75, suggesting a potential upside of 20.16%. Given AVITA Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe AVITA Medical is more favorable than Silk Road Medical.

Insider & Institutional Ownership

15.9% of AVITA Medical shares are owned by institutional investors. 7.8% of Silk Road Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AVITA Medical beats Silk Road Medical on 10 of the 14 factors compared between the two stocks.

AVITA Medical (NASDAQ:RCEL) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares AVITA Medical and Alphatec's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVITA Medical$14.26 million31.28$-42,030,000.00($2.07)-9.96
Alphatec$113.43 million14.45$-57,000,000.00($1.09)-15.81

AVITA Medical has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

AVITA Medical has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares AVITA Medical and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVITA MedicalN/AN/AN/A
Alphatec-51.95%-266.45%-40.80%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AVITA Medical and Alphatec, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVITA Medical00403.00
Alphatec00703.00

AVITA Medical currently has a consensus target price of $38.75, suggesting a potential upside of 86.75%. Alphatec has a consensus target price of $15.4286, suggesting a potential downside of 10.30%. Given AVITA Medical's higher possible upside, equities research analysts clearly believe AVITA Medical is more favorable than Alphatec.

Insider & Institutional Ownership

15.9% of AVITA Medical shares are owned by institutional investors. Comparatively, 31.8% of Alphatec shares are owned by institutional investors. 28.2% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AVITA Medical beats Alphatec on 7 of the 13 factors compared between the two stocks.

AVITA Medical (NASDAQ:RCEL) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares AVITA Medical and Pulmonx's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVITA Medical$14.26 million31.28$-42,030,000.00($2.07)-9.96
Pulmonx$32.60 million48.14$-20,700,000.00N/AN/A

Pulmonx has higher revenue and earnings than AVITA Medical.

Profitability

This table compares AVITA Medical and Pulmonx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVITA MedicalN/AN/AN/A
PulmonxN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AVITA Medical and Pulmonx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVITA Medical00403.00
Pulmonx03502.63

AVITA Medical currently has a consensus target price of $38.75, suggesting a potential upside of 86.75%. Pulmonx has a consensus target price of $58.00, suggesting a potential upside of 31.37%. Given AVITA Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe AVITA Medical is more favorable than Pulmonx.

Insider & Institutional Ownership

15.9% of AVITA Medical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Pulmonx beats AVITA Medical on 4 of the 7 factors compared between the two stocks.

AVITA Medical (NASDAQ:RCEL) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

15.9% of AVITA Medical shares are owned by institutional investors. Comparatively, 89.7% of Cardiovascular Systems shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares AVITA Medical and Cardiovascular Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVITA MedicalN/AN/AN/A
Cardiovascular Systems-10.12%-11.43%-8.36%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AVITA Medical and Cardiovascular Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVITA Medical00403.00
Cardiovascular Systems00703.00

AVITA Medical currently has a consensus target price of $38.75, suggesting a potential upside of 86.75%. Cardiovascular Systems has a consensus target price of $47.5714, suggesting a potential upside of 26.18%. Given AVITA Medical's higher possible upside, equities research analysts clearly believe AVITA Medical is more favorable than Cardiovascular Systems.

Volatility & Risk

AVITA Medical has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares AVITA Medical and Cardiovascular Systems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVITA Medical$14.26 million31.28$-42,030,000.00($2.07)-9.96
Cardiovascular Systems$236.54 million6.44$-27,240,000.00($0.79)-47.95

Cardiovascular Systems has higher revenue and earnings than AVITA Medical. Cardiovascular Systems is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Cardiovascular Systems beats AVITA Medical on 7 of the 13 factors compared between the two stocks.


AVITA Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.85-0.3%$1.75 billion$334.64 million94.49Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$51.50-2.9%$1.72 billion$63.35 million-42.21
Alphatec logo
ATEC
Alphatec
0.8$17.23-0.6%$1.63 billion$113.43 million-15.66Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.97-2.4%$1.61 billion$32.60 million0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$37.88-3.6%$1.47 billion$236.54 million-57.39
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.14-2.1%$1.38 billion$299.26 million-12.91
Atrion logo
ATRI
Atrion
1.1$652.25-1.1%$1.18 billion$155.07 million36.75
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$55.53-0.5%$1.08 billion$189.49 million-123.40
SI-BONE logo
SIBN
SI-BONE
1.2$33.00-0.1%$1.08 billion$67.30 million-20.62Increase in Short Interest
Cerus logo
CERS
Cerus
1.5$6.29-0.5%$1.05 billion$74.65 million-16.13News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$50.08-0.2%$1.03 billion$117.23 million53.85
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.50-0.9%$964.42 million$72.55 million-34.37
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.03-0.0%$916.43 million$264.16 million-5.38Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.54-1.1%$891.15 million$276.22 million-59.31
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.90-1.3%$847.99 million$459.95 million35.75
Surmodics logo
SRDX
Surmodics
1.3$57.41-0.1%$790.83 million$94.86 million717.63
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.25-0.7%$742.48 million$154.60 million-44.57
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.04-0.0%$679.37 million$123.86 million67.34
Intersect ENT logo
XENT
Intersect ENT
1.4$20.03-1.4%$652.07 million$109.14 million-10.49
Vapotherm logo
VAPO
Vapotherm
1.5$22.84-1.1%$595.63 million$48.10 million-10.88
SeaSpine logo
SPNE
SeaSpine
1.3$21.01-0.5%$589.95 million$159.08 million-12.58Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.55-0.3%$579.22 million$114.51 million-86.28Gap Down
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.64-1.4%$556.70 millionN/A-9.53
Accuray logo
ARAY
Accuray
2.3$5.27-0.9%$484.93 million$382.93 million37.64News Coverage
iCAD logo
ICAD
iCAD
1.5$18.77-3.6%$451.02 million$31.34 million-19.76
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.56-2.2%$415.73 million$11.22 million-46.73News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.03-2.0%$414.73 million$4.17 million-17.12News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.15-1.1%$400.19 million$24.95 million-27.73
PAVmed logo
PAVM
PAVmed
1.4$4.94-3.6%$392.51 millionN/A-6.50Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.90-1.2%$370.59 million$198.38 million24.95
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.28-0.8%$370.01 million$2.84 million0.00News Coverage
Soliton logo
SOLY
Soliton
1.1$17.32-4.0%$352.56 millionN/A-23.09
Neuronetics logo
STIM
Neuronetics
1.5$12.94-1.8%$322.94 million$62.66 million-7.70
Apyx Medical logo
APYX
Apyx Medical
1.0$9.40-0.2%$321.90 million$28.15 million-20.00Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.80-0.7%$317.93 million$46.90 million27.70
IRadimed logo
IRMD
IRadimed
1.5$25.05-2.3%$301.25 million$38.52 million78.28News Coverage
Gap Up
DarioHealth logo
DRIO
DarioHealth
1.3$18.57-0.0%$285.89 million$7.56 million-2.32
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.36-1.9%$273.47 million$220,000.0011.56
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.41-2.1%$204.92 million$8.34 million-2.04
TELA Bio logo
TELA
TELA Bio
2.1$14.11-1.5%$200.72 million$15.45 million-4.85
Titan Medical logo
TMDI
Titan Medical
1.2$1.68-1.2%$186.19 millionN/A168.00Analyst Report
PolyPid logo
PYPD
PolyPid
1.4$9.57-2.9%$163.13 millionN/A0.00Analyst Upgrade
Decrease in Short Interest
News Coverage
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.26-0.0%$144.99 million$23.16 million-326.00
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$10.93-0.9%$142.82 millionN/A0.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.50-2.0%$140.05 million$50.71 million-4.44Decrease in Short Interest
NMRD
Nemaura Medical
0.2$6.40-4.7%$139.87 millionN/A-32.00Increase in Short Interest
News Coverage
Avinger logo
AVGR
Avinger
1.4$1.30-3.5%$127.70 million$9.13 million-0.99Decrease in Short Interest
Gap Up
Venus Concept logo
VERO
Venus Concept
1.9$2.05-1.0%$111.72 million$110.41 million-0.61News Coverage
Gap Down
Beyond Air logo
XAIR
Beyond Air
1.7$5.55-2.2%$111.24 million$1.39 million-3.54Analyst Upgrade
News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.